Ask the expert: How can hallucinations affect people with Parkinson’s?
Author: Saskia MairPublished: 14 January 2021
Prep: Cook: Serves:
Around 50% of people with Parkinson’s disease will experience hallucinations. But what are they – and what causes them? In the latest in our ‘Ask the expert’ series, Professor Per Odin shares what you need to know about the symptom
What are hallucinations?
Hallucinations are sensory experiences that appear real but are created by our brains. They can affect all five of our senses. You might hear voices that no one else hears, or see things that no one else sees. They are normally separate from illusions, which are distorted or misinterpreted real perceptions – for example, you could see a person where there is actually a tree.
What causes hallucinations in people with Parkinson’s disease?
Hallucinations are very common in Parkinson’s disease. More than half of patients experience them at some stage. They are normally thought to be an effect both of the condition itself and of Parkinson’s medication. The risk of hallucinations increases with cognitive impairment, longer disease duration, age and other diseases.
Visual (seeing) and auditory (hearing) hallucinations may occur as a side effect of antiparkinsonian drugs which are used to treat the condition. They are often dose-dependent – and in principle reversible.
What types of hallucinations can people with Parkinson’s experience?
Visual hallucinations are the most common in Parkinson’s disease. Auditory hallucinations occur mainly in depression. Tactile (touch) or olfactory (smell) sensations are unusual.
Often the symptom starts with lively dreams, then illusions, then hallucinations at night-time. After that hallucinations can also appear in the day. Initially the patient understands that the experience is a hallucination, but if things progress it becomes difficult to say what is real and not.
Further progression could mean that the hallucinations become scary, and patients can develop confusion or delusions (for example, believing that a partner is unfaithful). Auditive hallucinations are seldom linked to Parkinson’s.
Mild hallucinations do not need to impact life very much, and can even be experienced as entertaining in some cases. But when the hallucinations become more pronounced and it is difficult to differentiate them from reality, they can have a big effect.
Per Odin is a neurologist, professor and head of the neurology department at Lund University, Sweden.
Can hallucinations be treated?
The treatment for hallucinations consists primarily of removing any existing medical cause, especially reducing or stopping any triggering pharmacological cause – for example by reducing a dose or discontinuing treatment with a certain drug. If the increase in motor symptoms then becomes troublesome, a return to the earlier anti-Parkinson’s drug may be considered, but with the addition of an atypical neuroleptic drug.
Most neuroleptics (drugs against hallucinations and psychosis) can worsen Parkinson’s (sometimes dramatically) and are forbidden when treating people with the condition. Medications for dementia can also reduce the incidence of illusions and hallucinations when there is underlying cognitive impairment. Parkinson’s treatments are developing fast and it is likely that we will see even more effective ways of avoiding and treating hallucinations in the coming years.
The most important thing is to report hallucinations to your doctor or nurse, and to discuss if they should be treated in some way.
Do you have any advice for the family, friends and carers of people with Parkinson’s experiencing hallucinations?
Tell the patient that what they are experiencing is not real and do not pretend that you also experience the same thing. Be calm and friendly with the patient – experiencing hallucinations can be quite stressful.
Need to know
Per Odin is a neurologist, professor and head of the neurology department at Lund University, Sweden. He also works at an outpatient clinic in Bremen, Germany. He has focused on Parkinson’s disease, both clinically and in research, since 1987.
Helping people with Parkinson’s “take back control of their brain and body”
We talk to the founder of MyCognition
7 days ago
New insights on immune cell process and Parkinson’s disease
Insoluble clumps of the protein alpha-synuclein, which can cause damage to brain cells, have been previously linked to Parkinson’s. Now, scientists in Germany, France and the US have uncovered new details on how brain cells respond to these clusters. The researchers discovered that the brain’s immune cells may be able to join together to break down the protein clumps. According to a press release, this was previously unknown. They also found that these neighbouring cells share mitochondria – structures that generate energy for chemical reactions – to help one another. In certain mutations associated with Parkinson’s, this process may be impaired. The researchers hope this insight could inform the development of new therapies. “We have opened the door to a field that will certainly engage researchers for many years to come,” said Professor Dr Michael Heneka, director of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at the University Hospital…
Could analysing skin oil help diagnose Parkinson’s disease?
Parkinson’s disease patients tend to have high levels of oil, known as sebum, on their skin’s surface. Now, a study has suggested that analysing this substance may help when diagnosing the condition. The study revealed that sebum contains significant amounts of genetic material, specifically the molecule ribonucleic acid (RNA). Analysis of RNA contained in sebum – that is, skin surface lipids RNA, or SSL-RNA – could offer insights into a person’s health. Researchers in Japan examined SSL-RNA in men and women with and without Parkinson’s. The results suggested that the SSL-RNA profiles of those with Parkinson’s had “different characteristics” than those without. The researchers then tested whether examining these profiles with machine learning could reveal those who had Parkinson’s – and who didn’t. The team’s algorithm indicated a “relatively robust discriminatory ability,” supporting the further use of SSL-RNA as part of a future “non-invasive” method for diagnosis.
‘Sonic hedgehog’ protein could impact Parkinson’s disease dyskinesia
Dyskinesia is often caused by extended use of the common Parkinson’s medication levodopa – and can be debilitating for those with the condition. Now, researchers in the US may have found a way to suppress these involuntary movements through a protein called ‘sonic hedgehog’. To conduct their study, the team administered levodopa and sonic hedgehog agonists to rodent and non-human primate models of the condition. The results revealed that dopamine neurons use the protein to communicate with other neurons thought to play a role in levodopa-induced dyskinesia. Increased signalling of sonic hedgehog pathways was found to reduce this dyskinesia – providing “novel insight” into its formation and a “potential therapeutic solution”. “What we find,” wrote corresponding study author Professor Andreas Kottmann, “is that in several animal models, by replacing … dopamine together with agonists that mimic the effects of sonic hedgehog, these dyskinesias can be very much suppressed.”